PROFILING CIRCULATING DNA AND RNA TO IDENTIFY MECHANISMS OF THERAPEUTIC RESISTENCE AND RESPONSE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Grant number: 1098647 | Funding period: 2018 - 2020

Completed

Abstract

Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cancers eventually become resistant to enzalutamide and not all men initially respond to treatment. I will look for blood markers that predict which men benefit from enzalutamide treatment and try to understand how resistance to enzalutamide occurs. This may lead to more effective use of enzalutamide resulting in better outcomes in advanced prostate cancer.

Related publications (9)

Scholarly works icon

1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention

T Scheinberg, M Fitzpatrick, H-M Lin, AA Azad, P Bonnitcha, AG Davies, G Heller, K Huynh, B Mak, K Mahon, P Meikle, D Sullivan, LG Horvath

2022-09-01

Scholarly works icon

Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

Arun A Azad, Ben Tran, Ian D Davis, Phillip Parente, Melanie Evans, Shirley Wong, Stephen Brown, Sue Evans, Jeremy Millar, Declan G Murphy, Nathan Papa

2022-05-31

BACKGROUND: Docetaxel has emerged as a standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). Uptake of doceta..

Scholarly works icon

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Blossom Mak, Hui-Ming Lin, Edmond M Kwan, Heidi Fettke, Tran Ben, Ian D Davis, Kate Mahon, Martin R Stockler, Karen Briscoe, Gavin Marx, Alison Zhang, Megan Crumbaker, Winston Tan, Kevin Huynh, Thomas G Meikle, Natalie A Mellett, Andrew J Hoy, Pan Du, Jianjun Yu, Shidong Jia

2022-03-25

BACKGROUND: Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumo..

Scholarly works icon

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial

Edmond M Kwan, Lavinia Spain, Angelyn Anton, Chun L Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu, Chao Dai, Pan Du, Shidong Jia, Heidi Fettke, Claire Abou-Seif, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Pezaro, Ben Tran

2022-02-26

BACKGROUND: Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest..

Scholarly works icon

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

Hui-Ming Lin, Blossom Mak, Nicole Yeung, Kevin Huynh, Thomas G Meikle, Natalie A Mellett, Edmond M Kwan, Heidi Fettke, Ben Tran, Ian D Davis, Kate L Mahon, Alison Zhang, Martin R Stockler, Karen Briscoe, Gavin Marx, Megan Crumbaker, Phillip D Stricker, Pan Du, Jianjun Yu, Shidong Jia

2021-10-14

BACKGROUND: Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20-30% of men with metastatic castrat..

Scholarly works icon

Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer

Heidi Fettke, Edmond M Kwan, Patricia Bukczynska, Jason A Steen, Maria Docanto, Nicole Ng, Phillip Parente, Andrew Mant, Siavash Foroughi, Carmel Pezaro, Christine Hauser, Tu Nguyen-Dumont, Melissa C Southey, Arun A Azad

2021-07-12

BACKGROUND: The androgen receptor (AR) pathway-associated gene nuclear receptor coactivator 2 (NCOA2) has an established oncogenic..

Scholarly works icon

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer

Edmond M Kwan, Heidi Fettke, Megan Crumbaker, Maria M Docanto, Sarah Q To, Patricia Bukczynska, Andrew Mant, Nicole Ng, Siavash Foroughi, Lisa-Jane K Graham, Anne-Maree Haynes, Sarah Azer, Lisi Elizabeth Lim, Eva Segelov, Kate Mahon, Ian D Davis, Phillip Parente, Carmel Pezaro, Tilman Todenhofer, Niranjan Sathianathen

2021-04-01

BACKGROUND: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed..

Scholarly works icon

Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer

Heidi Fettke, Edmond M Kwan, Maria M Docanto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K Graham, Kate Mahon, Christine Hauser, Winston Tan, Xiao Hong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Pan Du, Jianjun Yu, Yong Huang, Shidong Jia, Manish Kohli, Lisa G Horvath, Arun A Azad

2020-08-01

BACKGROUND: The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profi..

Scholarly works icon

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calven Wong, Pan Du, Shidong Jia, Siddhartha Yadav, Lisa G Horvath, Kate L Mahon, Edmond M Kwan, Heidi Fettke, Jianjun Yu, Arun A Azad

2020-04-01

BACKGROUND: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbation..